ARICEPT Drug Patent Profile

When do Aricept patents expire, and what generic alternatives are available?

Aricept is a drug marketed by Eisai Inc and is included in four NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in fifteen countries.

The generic ingredient in ARICEPT is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aricept

A generic version of ARICEPT was approved as donepezil hydrochloride by AUROBINDO on May 31^st, 2011.

Summary for ARICEPT

International Patents:	36
US Patents:	1
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	152
Patent Applications:	4,660
Drug Prices:	Drug price information for ARICEPT
What excipients (inactive ingredients) are in ARICEPT?	ARICEPT excipients list
DailyMed Link:	ARICEPT at DailyMed

See drug prices for ARICEPT

See drug sales revenues for ARICEPT

Recent Clinical Trials for ARICEPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Virginia	PHASE2
Changchun University of Chinese Medicine	EARLY_PHASE1
Vanderbilt University Medical Center	Early Phase 1

See all ARICEPT clinical trials

Pharmacology for ARICEPT

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Paragraph IV (Patent) Challenges for ARICEPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARICEPT	Tablets	donepezil hydrochloride	23 mg	022568		2013-07-09

US Patents and Regulatory Information for ARICEPT

ARICEPT is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	ARICEPT	donepezil hydrochloride	SOLUTION;ORAL	021719-001	Oct 18, 2004		DISCN	Yes	No
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	022568-001	Jul 23, 2010	AB	RX	Yes	Yes			Y
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996	AB	RX	Yes	No
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996	AB	RX	Yes	Yes
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-002	Oct 18, 2004		DISCN	Yes	No
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-001	Oct 18, 2004		DISCN	Yes	No

Expired US Patents for ARICEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	022568-001	Jul 23, 2010
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996

International Patents for ARICEPT

See the table below for patents covering ARICEPT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1116716
South Korea	20070086667	METHOD FOR STABILIZING ANTI-DEMENTIA DRUG
Germany	3855028
Czech Republic	9803960
Finland	962753
China	1312129
Germany	69739622

Supplementary Protection Certificates for ARICEPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0296560	98C0015	Belgium		PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21 303 19980415; FIRST REGISTRATION: GB - 10592/0078 19960228
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214

Market Dynamics and Financial Trajectory for Aricept (Donepezil)

Last updated: February 20, 2026

What is the market position of Aricept?

Aricept (donepezil) is a cholinesterase inhibitor approved by the U.S. Food and Drug Administration (FDA) in 1996 for treating mild to moderate Alzheimer’s disease. Its patent expired in most markets by 2016, leading to the proliferation of generic versions. As of 2023, Aricept remains a top-prescribed Alzheimer’s medication due to its established efficacy, safety profile, and brand recognition.

How does the current market landscape look?

Market size and revenue

The Alzheimer's drug market was valued at approximately $8.5 billion globally in 2022, with Aricept accounting for around 30-40% of prescriptions in North America and Europe. Its sales have declined from a peak of $2.5 billion in 2007, following patent expiration and generic competition, which reduced annual revenue to approximately $900 million by 2021.

Key competitors

• Generic donepezil: Dominates pricing and sales due to low entry barriers.
• Other branded drugs:
  • Rivastigmine (Exelon)
  • Galantamine (Razadyne)
  • Aducanumab (Aduhelm, approved for amyloid plaque reduction, not directly comparable but influences treatment landscape)

Market trends

• Shift towards disease-modifying therapies (DMTs) like aducanumab reduces reliance on symptomatic treatments like Aricept.
• Growing global aging populations sustain demand for Alzheimer's medications.
• Increased R&D in combination therapies exploring cholinesterase inhibitors with other mechanisms.

What are the financial trajectories for Aricept?

Revenue decline pattern

Year	Estimated Global Sales (USD millions)	Notes
2010	1,900	Peak sales, patent protection active
2016	1,500	Patent expiry, increase in generics
2018	1,050	Generic penetration deepened
2021	900	Stabilization at lower levels
2023	850-900	Slight rebound due to supply chain and healthcare demand

Cost structure

• R&D expenses diminished post-patent expiration.
• Marketing costs shifted toward generics and off-label use.
• Manufacturing costs are relatively stable due to generic production.

Profitability outlook

• Margins compressed from over 80% during patent-protected years to approximately 20-30% in the generic era.
• Sales are expected to stabilize or decline slightly in mature markets but remain steady in emerging economies where prescription barriers are lower.

How do regulatory and policy factors influence Aricept's market?

• Patent expiration in 2016 eliminated exclusivity in major markets.
• Pricing pressures from payers result in increasing use of generics, pressuring revenue.
• Adoption of new treatments targeting earlier stages of Alzheimer’s could reduce the proportion of patients receiving Aricept.
• Regulatory approvals of alternative therapies, including monoclonal antibodies, influence the treatment paradigm.

What are the prospects for future revenue and market share?

• Aricept's market share erodes as DMTs and combination therapies emerge.
• New formulations, such as extended-release tablets, have not significantly impacted the market.
• Developing countries provide growth opportunities, with minimal competition.
• Companies may develop fixed-dose combinations (FDCs) to sustain sales.

Which companies control Aricept’s market?

• Originally manufactured by Pfizer; now marketed by Eisai following licensing agreements.
• Generic manufacturers include Teva, Mylan (now part of Viatris), and Sun Pharmaceuticals.
• GSK and other competitors do not currently contest Aricept's core market but explore alternative Alzheimer’s treatments.

What are the dominant policies impacting market access?

• Price negotiations and formulary placements influence sales volume.
• Governments in Europe and Asia implement subsidy programs that sustain generic consumption.
• U.S. Medicare restrictions on off-label uses impact prescribing patterns.

What is the outlook for investment in Aricept’s market?

• Long-term decline in branded sales is unlikely to reverse without new formulations or indications.
• Short-term stability persists due to aging populations and unmet needs.
• Portfolio diversification into novel Alzheimer’s agents remains a strategic priority for pharmaceutical companies.

Key Takeaways

• Aricept’s sales peaked pre-patent expiry and declined sharply thereafter.
• Generic competition has driven prices and revenues down.
• The market is transitioning toward newer therapeutics, but Aricept remains part of treatment protocols.
• Opportunities exist in emerging markets and combination therapies.
• The product’s future depends on regulatory changes and innovation in Alzheimer’s treatment.

FAQs

1. Will Aricept regain market share with new formulations?
   No significant evidence suggests new formulations have boosted sales; market shift toward disease-modifying therapies reduces its prominence.

2. How does patent expiry affect generic drug pricing?
   Patent expiration allows generics, which are priced 80-90% lower than brand-name drugs, dominating sales and reducing overall revenue for the original manufacturer.

3. Are there prospects for Aricept in emerging markets?
   Yes. Lower pricing and less mature healthcare infrastructure sustain its use in regions like Asia and Latin America.

4. What impact do new Alzheimer's drugs have on Aricept sales?
   They could reduce the pool of patients using symptomatic treatments, potentially further shrinking Aricept’s revenue.

5. Does ongoing research threaten Aricept’s market position?
   Not directly. While new drugs might replace symptomatic treatments eventually, Aricept’s established safety profile and low cost make it a fallback option.

---

References

[1] Grand View Research. (2022). Alzheimer’s Drugs Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Prescriptions Data.
[3] U.S. Food & Drug Administration. (1996). Approval Letter for Aricept.
[4] European Medicines Agency. (2015). Summary of Product Characteristics: Donepezil.
[5] MarketWatch. (2023). Alzheimer’s Disease Drug Market Forecasts and Trends.